Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.

NCT00951210 is registered in ClinicalTrials.gov with Pluristem Ltd. as lead sponsor.

NCT NCT00951210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00951210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.
Lead sponsor
Pluristem Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2009
Completion date
October 31, 2011
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia, peripheral artery disease, peripheral vascular disease